Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by MrMugsyon Jul 17, 2021 1:57pm

162 Views

Post# 33565355

When this was 10 cents ...

Correct Yukon .. at 10 cents, I did most of my buying.
Then it dropped to 8 cents and I did even more buying.

I just don't make my buying/selling decisions based on what retail shareholders think.
I'm definitely not going to follow McWhirter in and out of an investment.
I'm also not going to panic based on what retail shareholders think.
You should know that by now - unless you're new to investing.
Take notes - it might help you.

Regardless ... good luck to you !

: )

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages